Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease

Area of Science:

• Cardiology and Pharmacology

Background:

• Cardiovascular diseases (CVD) are a significant cause of premature death and disability globally, particularly in India.
• In India, non-communicable diseases (NCDs) account for 52% of mortality, with CVDs comprising 66% of NCD-related deaths.
• Effective secondary prevention strategies are crucial for patients with existing CVD, such as myocardial infarction (MI) or revascularization, to reduce mortality and improve quality of life.

Purpose of the Study:

• To explore the available data on the role of rosuvastatin in the secondary prevention of cardiovascular diseases.
• To evaluate rosuvastatin's efficacy in achieving lipid goals and its impact on surrogate markers of cardiovascular risk reduction.

Main Methods:

• This article reviews existing clinical evidence and data concerning rosuvastatin's use in secondary prevention.
• The review focuses on studies assessing LDL cholesterol reduction, achievement of LDL goals, and effects on intima-media thickness and inflammatory markers.

Main Results:

• Rosuvastatin demonstrates potent HMG-COA reductase inhibition, leading to effective LDL cholesterol reduction.
• Clinical evidence suggests rosuvastatin enables more patients to achieve their LDL goals compared to other statins.
• Studies indicate rosuvastatin's effectiveness in reducing intima-media thickness, a marker of atherosclerosis progression.

Conclusions:

• Rosuvastatin shows significant potential as a therapeutic option for secondary prevention of cardiovascular diseases.
• Its efficacy in achieving LDL goals and improving surrogate markers supports its role in managing patients at high cardiovascular risk.
• Further clinical data specifically focused on secondary prevention outcomes with rosuvastatin is warranted.